MAYO CLINIC

Eisai reports 3% Q2 FY2024 revenue growth to JPY 385 billion, driven by a 5% increase in the pharmaceutical segment, led by Lenvima, Dayvigo, and LEQEMBI. Despite a decline in operating profit due to increased SG&A expenses, the company maintains its full-year forecast and announces an interim dividend of JPY 80 per share. LEQEMBI's U.S. launch contributes JPY 16.3 billion in H1 sales, with 10,000 patients ready for treatment, though 6,000 face infusion delays. Eisai focuses on expanding infusion capacity and improving amyloid beta testing efficiency to enhance patient access and future profitability.

Eisai reports 3% Q2 FY2024 revenue growth to JPY 385 billion, driven by a 5% increase in its pharmaceutical segment. Despite a slight dip in operating profit to JPY 27.8 billion, flagship products like LEQEMBI show promising growth. LEQEMBI sales reach JPY 16.3 billion globally in H1 FY2024, with significant growth in the U.S. and China. The company maintains full-year revenue and profit forecasts and announces an interim dividend of JPY 80 per share. Eisai focuses on cost control and key product growth, with optimism for future market expansion despite infusion capacity constraints delaying treatment for 6,000 patients.

Mayo Clinic study finds GLP-1 receptor agonists and SGLT2 inhibitors may reduce heart attacks, second strokes, and death in ischemic stroke survivors, with a 74% lower risk of death and 84% lower risk of heart attack. SGLT2 inhibitors showed a 67% lower risk of second stroke. The study, though limited by geographic and ethnic factors, suggests potential for clinical practice.

Industry experts discuss diversity in clinical trials, financial toxicity in cancer treatment, U.S. agency warns of China-linked phone hack, free heart & kidney health screenings in Houston, and the growth of the global radiopharmaceutical market.

Weight-loss drugs like Ozempic and SGLT2 medications reduce stroke survivors' risk of death and heart attack by 74% and 84% respectively, and lower second stroke risk by 67%.

New hourglass-shaped stent improves angina symptoms in patients with microvascular disease, restoring blood flow to tiny heart vessels, according to Mayo Clinic researchers.

Digital health startups Aignostics, TCC, Yazen Health, Nema Health, Alimetry, and Research Grid secure significant funding. Aignostics raises $34M for AI in digital pathology, TCC gets €20M for ICU telemedicine, Yazen Health secures €19.5M for obesity care platform, Alimetry receives $18M for GI disorder diagnostics, Nema Health raises $14.5M for PTSD treatment, and Research Grid collects £5M for clinical trial automation.

Mayo Clinic's Dr. Keith Knutson has seven breast cancer vaccines in clinical trials, aiming to boost the immune system and extend patient lives. Half of these vaccines are in phase two, nearing availability.

The article discusses the requirement of enabling JavaScript to view a page, with a message indicating JavaScript is necessary for access.

The article contains a PDF document with metadata indicating it was created using Adobe Photoshop CS6 on Windows, with references to instance and document IDs.